GenVec Inc (fka GNVC)

[skitahoe]

If I understood correctly, a partner will be for TNFerade and advance it in all indications it selects to, i.e. the partner will take control, as Novartis has with our hearing drug. Any partner that has the financial and technical support needed to advance the drug should be greeted warmly by shareholders. We'll probably never know the size of the partnerships previously turned down by GNVC, but any reasonable offer should dramatically advance the stock.

I believe there is one Joker still remaining, this trial:

http://clinicaltrials.gov/ct2/show/NCT00868114?term=TNFerade&rank=8

If by chance substantially more efficacy is seen in the group taking TNFerade with another experimental drug then in the experimental drug alone, together they may move into a Pivotal or Registrational Trial. You'll note this trial is not being run by GNVC and currently is being done just in the one site. The trial should complete sometime this year, it was originally scheduled for last year. If positive, this trial could be a real game changer, especially if positive data is seen in Pancreatic Cancer with limited Mets.

Gary